Tag: Endovascular Engineering
E2 raises US$80 million series C financing for Hēlo thrombectomy platform
Endovascular Engineering (E2) today announced an oversubscribed US$80 million series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors including...
PE thrombectomy: ENGULF pivotal study meets safety and efficacy endpoints
Full results from the ENGULF pivotal study of the Hēlo thrombectomy system (Endovascular Engineering) in acute intermediate risk pulmonary embolism (PE) patients demonstrated a...
Endovascular Engineering’s ENGULF pivotal trial completes patient enrolment
Endovascular Engineering (E2) has completed patient enrolment in the pivotal cohort of its ENGULF trial, involving the Hēlo pulmonary embolism (PE) thrombectomy system.
The investigational...
Endovascular Engineering announce first patient enrolled in PE thrombectomy trial
Endovascular Engineering, a medical device company involved with clot removal technologies for venous thromboembolism (VTE), has announced the enrolment and treatment of the first...
E2 shares positive initial results from use of Hēlo system for...
Endovascular Engineering (E2) has announced positive initial results from its ENGULF study, demonstrating successful outcomes among the first 15 patients evaluated in the trial...
